{
    "clinical_study": {
        "@rank": "97312", 
        "arm_group": [
            {
                "arm_group_label": "Treatment sequence 1 (AEBD)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment sequence 2 (BACE)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment sequence 3 (CBDA)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment sequence 4 (EDAC)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment sequence 5 (DECA)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment sequence 6 (EADB)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment sequence 7 (ABEC)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment sequence 8 (BCAD)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the pharmacokinetics and relative bioavailability\n      of 4 new formulations of fentanyl transdermal patch in healthy participants after a single\n      application for 72 hours."
        }, 
        "brief_title": "A Study to Assess the Relative Bioavailability of 4 Formulations of Fentanyl Transdermal System Compared Against DUROGESIC Fentanyl Transdermal Patch After Single Application in Healthy Volunteers", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "This is an open-label (all people know the identity of the intervention), randomized (the\n      study drug is assigned by chance), 4-way crossover (participants will receive different\n      interventions sequentially during the trial) study. The study will assess the\n      pharmacokinetics (how the drug is absorbed in the body, distributed within the body, and how\n      it is removed from the body over time) and relative bioavailability (the extent to which a\n      drug or other substance becomes available to the body) of 4 new formulations of fentanyl\n      transdermal patch, TDS-Concept 1 50 \u00b5g/h, TDS-Concept 2 50 \u00b5g/h, TDS-Concept 3 50 \u00b5g/h and\n      TDS-Concept 4 100 \u00b5g/h compared with DUROGESIC fentanyl 50 \u00b5g/h in healthy participants\n      after a single application. All participants will be randomly assigned to 1 of 8 possible\n      treatment sequences. During the 4 single-application treatment periods, each transdermal\n      patch will be worn, on a different application site on the lateral side of the upper arm,\n      continuously for 72 hours. The treatment periods will be separated by a washout period\n      (period when receiving no treatment) of at least 8 and no more than 14 days. The total study\n      length is from 64 days to a maximum of 82 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body mass index (BMI; weight [kg]/height2 [m]2) between 18 and 30 kg/m2 (inclusive),\n             and body weight not less than 50 kg\n\n          -  Participants must utilize a medically acceptable method of contraception throughout\n             the entire study period including the washout period and for 3 months (men) or 1 week\n             (women) after the study is completed\n\n          -  Men must not donate sperm from the first drug administration until 3 months after\n             completion of the study\n\n          -  Each participant will receive a test for opioid dependency. Only those participants\n             that pass this challenge test will be allowed to continue in this study\n\n          -  Non-smoker\n\n        Exclusion Criteria:\n\n          -  History of or current clinically significant medical illness, disease or condition\n             that the investigator considers should exclude the subject or that could interfere\n             with the interpretation of the study results\n\n          -  Clinically significant abnormal laboratorial values\n\n          -  Clinically significant abnormal physical examination, vital signs or\n             electrocardiogram (ECG)\n\n          -  Use of any prescription or nonprescription medication (including vitamins and herbal\n             supplements), except for paracetamol, oral contraceptives and hormonal replacement\n             therapy within 14 days before the first dose of the study drug is scheduled\n\n          -  History of, or a reason to believe a participant has a history of drug or alcohol\n             abuse within the past 5 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01717157", 
            "org_study_id": "CR100879", 
            "secondary_id": [
                "FENPAI1022", 
                "2012-000705-71"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Treatment sequence 1 (AEBD)", 
                    "Treatment sequence 2 (BACE)", 
                    "Treatment sequence 3 (CBDA)", 
                    "Treatment sequence 4 (EDAC)", 
                    "Treatment sequence 5 (DECA)", 
                    "Treatment sequence 6 (EADB)", 
                    "Treatment sequence 7 (ABEC)", 
                    "Treatment sequence 8 (BCAD)"
                ], 
                "description": "One DUROGESIC transdermal patch containing 8.4 mg of fentanyl applied on the skin for 72 hours.", 
                "intervention_name": "Treatment A: DUROGESIC (8.4 mg fentanyl)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment sequence 1 (AEBD)", 
                    "Treatment sequence 2 (BACE)", 
                    "Treatment sequence 3 (CBDA)", 
                    "Treatment sequence 6 (EADB)", 
                    "Treatment sequence 7 (ABEC)", 
                    "Treatment sequence 8 (BCAD)"
                ], 
                "description": "One transdermal system-concept 1 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.", 
                "intervention_name": "Treatment B: Transdermal System-Concept 1 (6.2 mg fentanyl)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment sequence 2 (BACE)", 
                    "Treatment sequence 3 (CBDA)", 
                    "Treatment sequence 4 (EDAC)", 
                    "Treatment sequence 5 (DECA)", 
                    "Treatment sequence 7 (ABEC)", 
                    "Treatment sequence 8 (BCAD)"
                ], 
                "description": "One transdermal system-concept 2 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.", 
                "intervention_name": "Treatment C: Transdermal System-Concept 2 (6.2 mg fentanyl)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment sequence 1 (AEBD)", 
                    "Treatment sequence 3 (CBDA)", 
                    "Treatment sequence 4 (EDAC)", 
                    "Treatment sequence 5 (DECA)", 
                    "Treatment sequence 6 (EADB)", 
                    "Treatment sequence 8 (BCAD)"
                ], 
                "description": "One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.", 
                "intervention_name": "Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment sequence 1 (AEBD)", 
                    "Treatment sequence 2 (BACE)", 
                    "Treatment sequence 4 (EDAC)", 
                    "Treatment sequence 5 (DECA)", 
                    "Treatment sequence 6 (EADB)", 
                    "Treatment sequence 7 (ABEC)"
                ], 
                "description": "One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.", 
                "intervention_name": "Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fentanyl"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Healthy", 
            "Fentanyl", 
            "Transdermal patch", 
            "DUROGESIC"
        ], 
        "lastchanged_date": "March 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Antwerp", 
                    "country": "Belgium"
                }
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "8", 
        "official_title": "An Open-Label, Randomized, 4-Way Crossover Study to Assess the Relative Bioavailability of 4 New Formulations of Fentanyl Transdermal System Compared Against DUROGESIC Fentanyl Transdermal Patch After Single Application in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Janssen Research & Development, LLC", 
            "last_name": "Janssen Research & Development, LLC Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Fentanyl serum concentrations", 
                "safety_issue": "No", 
                "time_frame": "Up to 120 hours after applying the transdermal patch"
            }, 
            {
                "description": "The fentanyl content in the patchs following their removal at the end of 72 hours", 
                "measure": "Determination of residual fentanyl content in the worn patchs", 
                "safety_issue": "No", 
                "time_frame": "At the end of 72 hours after applying the transdermal patch"
            }, 
            {
                "description": "The patch adherence will be scored from 0 to 4, where 0: >= 90% of the area adhered and no edges unattached; 1: >= 75% to < 90% adhered; 2: >= 50% and < 75% adhered; 3: > 0% and < 50% adhered, but not detached; 4: 0% adhered - patch detached.", 
                "measure": "The skin adherence score of the patches", 
                "safety_issue": "No", 
                "time_frame": "Up to 72 hours after applying the transdermal patch"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01717157"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "The incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "Approximately 82 days"
        }, 
        "source": "Janssen Research & Development, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Research & Development, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}